Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 4;15(19):4852.
doi: 10.3390/cancers15194852.

Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study

Stefania Gori  1 , Alessandra Fabi  2 , Catia Angiolini  3 , Monica Turazza  1 , Piermario Salvini  4   5 , Gianluigi Ferretti  6 , Elisabetta Cretella  7 , Lorenzo Gianni  8 , Claudia Bighin  9 , Angela Toss  10   11 , Claudio Zamagni  12 , Patrizia Vici  13 , Costanza De Rossi  14 , Antonio Russo  15 , Giancarlo Bisagni  16 , Antonio Frassoldati  17 , Lucia Borgato  18 , Anna Cariello  19 , Claudia Cappelletti  20 , Roberto Bordonaro  21 , Saverio Cinieri  22 , Alessandra Modena  1 , Matteo Valerio  1 , Maria Francesca Alvisi  23 , Irene De Simone  23 , Francesca Galli  23 , Eliana Rulli  23 , Anna Santoni  23 , Fabrizio Nicolis  24
Affiliations

Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study

Stefania Gori et al. Cancers (Basel). .

Abstract

To evaluate the rate of early breast cancer (EBC) patients treated with neoadjuvant systemic therapy (NAT) in Italy, criteria of patient selection and types of therapies delivered, an analysis of 1276 patients with stage I-II-III was conducted out of 1633 patients enrolled in the multicenter prospective observational BRIDE study. A total of 177 patients (13.9%) were treated with NAT and 1099 (85.9%) with surgery; in multivariate analysis, menopausal status, cT, cN, grade, HER2-positive and Triple negative (TN) subgroups were significantly associated with the decision to administer NAT. The type of NAT delivered was influenced by EBC subtype. NAT was administered to 53.2% of HER2+/HR-negative, 27.9% of HER2+/HR+, 7.1% of HER2-negative/HR+ and 30.3% of TN EBC patients. The pCR rates were similar to the ones reported in the literature: 74.2% in HER2+/HR-negative, 52.3% in HER2+/HR+, 17.2% in HER2-negative/HR+ and 37.9% in TN. In clinical practice, patient and tumor characteristics influenced oncologists in the decision to administer NAT in EBC and in the choice of the type of systemic therapy, according to ESMO and AIOM Guidelines. Currently, it is recommended always to evaluate the use of NAT in EBC, mainly in HER2+ and TN patients, considering that pCR is associated with significantly better survival of the patient and that effective therapies are now available for residual disease.

Keywords: criteria of choice of neoadjuvant therapy; early breast cancer; pathological response; types of neoadjuvant therapy.

PubMed Disclaimer

Conflict of interest statement

A.F. advisory role for Roche, Astrazeneca, Lilly, Novartis, Seagen, Daiichi Sankyo, Gilead, Exact Science, Pfizer, outside the submitted work; P.V. Advisory Board/speaker fee: Novartis, Lilly, Eisai, Ipsen, Pfizer, Institutional/Travel Grant: Roche, Novaris, Pfizer, Lilly, Eisai; A.T. Lilly, Novartis, Pfizer, Gilead, Seagen, MSD, Astrazeneca, Daiichi Sankyo.

Figures

Figure 1
Figure 1
Study profile. * In this analysis, 289 patients were not evaluated because information on clinical stage at diagnosis was needed to assess the criteria used by oncologists for starting neoadjuvant systemic therapy.
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerejomataram I., Jemal A., Bray F. Glòobal Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
    1. Decessi per Tumore e Sesso in Italia Durante l’anno 2017—Dati ISTAT. [(accessed on 15 May 2023)]. Available online: http://dati.istat.it/Index.aspx?DataSetCode=DCIS_CMORTE1_EV#.
    1. Fondazione AIOM- AIRTUM-PASSI I Numeri del Cancro in Italia 2020. [(accessed on 15 May 2023)]. Available online: www.fondazioneaiom.it.
    1. Kesson E.M., Allardice G.M., George W.D., Burns H.J.G., Morrison D.S. Effects of multidisciplinary team working on breast cancer survival: Retrospective, comparative, interventional cohort study of 13,722 women. Br. Med. J. 2012;344:e2718. doi: 10.1136/bmj.e2718. - DOI - PMC - PubMed
    1. Vrijens F., Stordeur S., Beirens K., Devriese S., Van Eycken E., Vlayen J. Effect of hospital volume on processes of care and 5-year survival after breast cancer: A population-based study on 25,000 women. Breast. 2012;21:261–266. - PubMed

Grants and funding